Stats

The fund started with $49.14 in cash and $850.99 in equity, with no open or pending trades. The goal is to achieve repeatable net gains before catalysts occur. A catalyst is an event that can affect a stock's price. The fund's strategy is based on an independently validated executable edge, which means a proven method of making trades, not just affordability. The fund's approach is based on several premises: 1) there are 13,154 non-test symbols on the Nasdaq exchange, but only 8,066 had fresh prices on September 4; 2) High Tide Inc. (HITI) will announce its third fiscal quarter 2026 financial results on September 14, but preliminary guidance was already disclosed on August 4; 3) Hain Celestial Group (HAIN) earnings were confirmed, but organic volume weakness and debt complicate recovery; 4) several companies, including Nike (NKE) and General Mills (GIS), have upcoming events, but these are just research candidates, not tested trades. The fund's analysis is limited by small sample sizes, partial venue prices, and pre-announcement regimes. Despite these limitations, the fund will continue to collect data and verify new studies before making trades. The fund's current size is zero, with a fund cap of $49.14 and an account position cap of $212.75. The risk budget is $8.50, which has never been loosened due to funding pressure.

A news scan found the headline 'Sep6screen' which refers to a September 6 screen of US listing symbols. This screen found 13,154 unique symbols, including 5,584 Nasdaq listed and 7,571 other listed non-test symbols. The screen used data from Nasdaq Trader files from September 4. Of these symbols, 12,633 were compatible with the API, and 12,594 had a snapshot returned, with 12,436 having a price. However, only 8,066 had September 4 bars, and 4,370 had stale prices. A review of 29 weekday Nasdaq earnings calendars from September 8 to October 16 found 346 unique tickers, with 345 priced and 302 fresh. One symbol, MKC.V, was unquoted. The calendar estimates leads, but these are not proof from the issuer, and there is no coverage of over-the-counter stocks, with 521 syntax exclusions. The fresh candidates were sorted by IEX dollar volume, with an affordability of 49.14, and volume is partial venue. Two symbols, NKE at 38.41 on October 1, and GIS at 38.28 on September 23, were confirmed by the issuer, but are still being watched, with no fixed edge yet. MU and TSM were found to be expensive for whole shares, and TSM has a calendar lead on October 15, but this is not confirmed on the issuer's agenda, which does confirm a monthly revenue on September 10 at 13:30 Taipei time. HITI at 2.57 on September 14 had an AMC test that failed due to uncertainty, and HAIN at 7.521 on September 14 had a turnaround edge that was unvalidated, and BFRI at 1.625 on September 28 has a PDUFA risk. Non-US symbols with six quotes from Japan, the UK, Canada, Hong Kong, and Spain include DATA.L on September 14, which had confirmed results, and ET.TO on September 14, which had a confirmed call, but 4431.T and 0513.HK have dates that remain secondary leads. ITX and NXT are prior verified monitors that have been retained. There is no local venue or FX edge that has been validated. The sources used include Nasdaq Trader, Nasdaq API, and various investor relations websites. The statistical screen is for discovery, not a backtested trading strategy, and does not claim full market coverage. There is no assertion that the sources missed any proven event.

A review of Solana's upgrade schedule reveals inconsistencies. The Solana overview states that Agave 4.3 is scheduled for October 2026, while the Alpenglow detail page says it will happen in Q3. The main transaction page mentions mainnet activation and links to the Agave 4.2 schedule, which lists August 18 as the start of generic feature activations, but not the specific September 9 txV1 activation. As of September 2, the developer tracker still classifies txV1 as pending on the devnet, while the foundation page updated in August reports that the devnet is active. The dates and status need to be reconciled with independent sources. The first step of rent on September 3 is consistent with the pending status on the September 2 tracker, considering different timestamps. A prior analysis of ETH found a discrepancy between the September 6 decision and the stale September 28 monitor. The conclusion is that there is no validated net event edge and no verified exact activation epoch for crypto allocation. Validity requires all gates, and soundness is limited to accessible documents, which does not prove September 9 is false. A counterexample could be the original Foundation VP post or feature configuration, which may confirm and repair the date but not profitability. Sources include Solana's upgrade pages and GitHub repositories. No new crypto trade or date-only automatic action is taken, and no unrelated protocol-event strategy is promoted.

The research decision made on September 6 is to retain $49.14 in cash and not make any new entries or resets. At the start, there were no holdings or queued orders, with $49.14 in fund cash and $850.99 in account equity. The goal is to achieve repeatable net pre-event gains. A key constraint is that any decision must be based on an independently validated executable edge, which means a proven and reliable advantage in trading. The decision is based on the following premises: 1) a direct trade and monitor audit observation on August 28, 2024, showed nothing to exit or adjust. 2) The issuer of LEN confirmed that the earnings release will be on September 16 after close, not on September 17, and various tests failed to authorize a thesis attack. 3) The after-hours session on September 9 left only the September 8 session with no tested intraday edge, and questions about payoff and venue for ADBE and NEXT dates remain unresolved. 4) Existing rejections of GRAL, CPRT, and CHWY were not changed by another calendar check. 5) The issuer of IONS confirmed on September 4 that there was an already-reported clinical miss, not a new pending catalyst, and a biochemical response cannot substitute for clinical benefit. The sources for this information include news releases from Lennar Corporation, Academy Sports and Outdoors, Adobe, Next PLC, and Ionis Pharmaceuticals. The validity of the decision is based on requiring a pending date, validated net edge, and execution access together, which implies no proposal. The soundness of the decision is established by sources that confirm dates and tests that establish selected historical payoffs. The strongest objection to the decision is that a LEN overlay is nominally profitable. However, this is responded to by noting the small sample size, uncertainty, and cost sign reversal, with a whole-share price of $83.57 above the $49.14 cap. The consequences of retaining cash are that there is no gap exposure before the next 02UTC run, no chance to profit from an unvalidated rebound, and preserved capital permits future validated entry. New monitors 31-34 are for research only, and existing jobs on September 17 will continue, with no additional collection required before the next 02UTC research and no orders queued. A separate decision audit on ETH identifies October 6 as the replacement for the stale September 28 roadmap, which is not a catalyst order. Research gaps remain recorded, and no risk is added to meet the $349.01 funding shortfall.

The trading fund started with $49.14 in cash, aiming for repeatable net gains. This audit reviewed saved research, not new strategy or backtest. Three main points were considered: (1) only 3 closed trades and 13 monitors were found, with no exits or adjustments needed before the next run on September 6 at 00UTC. (2) 132, 113, and 38 tests showed negative results, including GRAL with a -36.2152% return, CPRT with a -4.2620% return, and CHWY with a -1.719988% return. (3) checks on regulator and issuer pages showed upcoming events for GRAL, but no new information was found. (4) previous news about IONS was reviewed again, but no new evidence was found to support a change. The conclusion is to keep all cash and existing research monitors. The audit is valid because it requires a numerical edge, and unsupported entries cannot be made based on confirmed dates alone. However, the audit has limitations, such as small sample sizes and biased live records. The strongest counterargument is that upcoming optimism could rally stocks, but no measured positive payoff was provided. To change the current size, a separately preregistered positive net event holdout, valid current entry window, complete pipeline, and feasible venue exits are needed. The fund benefits only if net realizable payoff exceeds costs. A new briefing may change expectations, leading to gaps that can bypass planned stops, resulting in losses that reduce deployable capital. No fresh indicators, simulation, or test rerun is warranted with no eligible entry or changed rule. The fund will retain $49.14 in cash.

The automated trading fund manager has decided not to allocate funds to Galleri, despite its upcoming FDA panel on September 23. The decision is based on several premises, including the lack of guarantee on when background materials will be published, conflicting clinical endpoints, and the failure of the NHS primary stage III/IV reduction. The manager also considered the company's cash burn, dilution, and impaired commercial asset, as well as the loss of 36.215% net in 13 chronological holdout trades. The current trigger is false, and the manager will retain $49.14 in cash. The decision is limited by the selected historical prices, daily fills, and small samples, but the manager has concluded that there is no defensible pre-event run-up based on the available evidence. The manager will continue to monitor the situation, but no live holdings or queued orders need review or adjustment.

The automated trading fund manager made a decision on September 5 at 02UTC to widen the search for catalysts and retain all cash. The manager started and ended with $49.14 in cash and no holdings or queued orders, with no current exits to adjust. The manager considered lessons such as company-wide binary inventory, primary endpoint distinction, exact release and call timing, and no recovery sizing. The manager screened 13,155 directory rows and found 214 estimated US earnings candidates, 254 date-matched foreign leads, and a bounded crypto scope. However, 40 affordable price uptrends were not eligible trades. The manager rejected NUVL due to a stale pending date after FDA approval on July 22. The manager also considered GRAL, TLX, and SRRK, but their pipeline, approval probability, payoff, and gap limits were unresolved. The manager tested CPRT and found that it failed the net chronological holdout test with a return of -4.262%. The manager also considered prior rejections of CHWY, KR, GME, and ADBE, which remained unchanged. The manager found that CNXC's date was unverified, while BRZE and CASY had their next open event day. The manager concluded that there would be no propose, exit, adjust, or fund actions. The manager's decision was based on required numerical edge and soundness bounded by small selected event history, partial IEX, estimated calendars, foreign pagination, and unmodeled 15-minute exits. The manager noted that good fundamentals and rising prices can rally, but this does not repair negative tested payoffs or unknown approval edge. The manager started with cash, aimed for repeatable net gains, and implemented a binding constraint with independent positive expectancy. The manager recorded various metrics, including fundamental, statistical, simulation, technical, and consequences. The manager also monitored new research and tested an FDA collector job. The manager did not require any action before 04UTC and preserved the final recording phase. The manager provided original URLs for observations and analyses, including FDA documents and press releases. The research finished around 02:21, within the 45-minute ceiling. No other fund monitors or trades were modified.

On September 5 at 02:00, research was conducted. It involved looking at 13,155 securities listed on NasdaqTrader, which includes 5,584 Nasdaq securities and 7,571 securities from other exchanges, as well as 7,499 non-ETF rows including non-common instruments. These were cross-checked with 19 weekday Nasdaq earnings-calendar requests from September 8 to October 2. The result was 214 unique listed candidates, but 122 of these calendar rows did not have a release time. It's important to note that these are estimates and not confirmations from the issuers. Daily bars from IEX were fetched for all 214 candidates, plus six comparison and regulatory names, and 218 out of 220 had at least 51 observations. A filter was applied where the price is greater than the 20-day simple moving average, which is greater than the 50-day simple moving average, and the close is less than or equal to 49.14, leaving 40 candidates. These were then ranked by observed IEX dollar volume, with CPRT being the first. This process is a screening and not a validated strategy or a complete current common-stock history. International RTT pages returned 419 rows, but 99 were rejected because their displayed date differed from the requested day, leaving 320 date-matched rows, of which 254 were classified as foreign due to their suffix. Only the first-page coverage and six selected foreign quotes were considered, and this was not an exhaustive global price census. The Coinbase 409-currency catalog was not used as a venue universe or a dated catalyst list because protocol upgrades are outside this fund's earnings and FDA mandate. The ETH date review belongs to the existing Crypto monitor. The primary-source work, not secondary dates, determines eligibility. The validity of the candidates can be generated without accepting estimated dates, but the soundness is limited by directory survivorship, missed calendar companies, pagination, and partial IEX liquidity. The names that were rejected due to missing dates remain ineligible and are not considered bearish. The sources used for this research include https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt, https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt, https://api.nasdaq.com/api/calendar/earnings?date=2026-09-09, https://www.rttnews.com/Calendar/Earnings.aspx?Date=08-Sep-2026, https://api.exchange.coinbase.com/currencies, and https://runway.adityaperswal.workers.dev/data/stock-bars.

The automated trading fund manager has concluded its research for September 5. The Direct Catalyst ledger is flat with three closed trades and no pending or open lots, so no stops or targets need to be reset. The manager's record is 0-3, including two forced liquidations, and it cannot establish a natural strategy edge. An independent test of the CHWY calendar failed with a net loss of 1.72%, and the prior rejection of ADBE, KR, and GME remains. The calendar test is not a viable stop or target strategy, and the current entry date has already passed. The MIRM primary and secondary distinction, as well as the AZURE1 Q3 overlap, undermine the prior single-PDUFA narrative. The IONS September 4 pelacarsen failure is confirmed, and RARE's previous pipeline failure resulted in a 45.86% loss. Measured ranges, simulation, and whole-share limits do not make the strategy eligible. The conclusion is to keep 49.14% of the cash and make no new orders, exits, or adjustments. The validity of the strategy is based on numerical edge and overlap rules, but its soundness is limited by a small historical sample and other factors. A counterargument could be that consumer growth or secondary biotech efficacy could lead to a future rally, but this does not identify a positive executable expectancy. The manager's goal is to achieve repeatable net returns with a binding constraint of independent positive implementable event edge. The manager will monitor CHWY, KR, MIRM, and GME, and job 9 remains informational and active. The source URLs for the analyses are provided, including https://runway.adityaperswal.workers.dev/data/stock-bars, https://ir.ionispharma.com/static-files/a612d86f-2531-470a-9340-5e0db04932c9, and https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx.

A review of the trading system was conducted at 21:18. The system retains its cash position because no validated trading opportunity, or edge, was found. The system looks at past trades, including 3 trades with a return of -2.45%, to decide what to do. A win rate of 33.3% was recorded, but this is not a reliable estimate of future performance. The system also looks at the history of stocks like ADBE and GME, but their past gains do not change the decision to retain cash. The system has no active trades and no pending trades. The Kroger company, whose stock is ticker KR, announced a conference call for September 11 at 08:00 ET, but this does not affect the decision to retain cash. The system will keep its cash position at $49.14. The decision is based on the lack of a validated trading edge, which means there is no reliable way to make a profit. The system will continue to look for a repeatable way to make a profit, but for now, it will not make any trades. The next review will be on September 5 at 00:00 UTC.

The automated trading fund manager reviewed the trading strategy at 21:05 and decided to retain cash. The review was based on four premises. Premise 1 looked at past research notes and found that the current strategy, which has been tested over 10 sessions, has a -2.45% return, with 3 events and a 33.3% win rate, and no new validated rule was found. Premise 2 checked the current trades and monitors, and found that there are no queued orders and the available capital is $49.14. Premise 3 confirmed that Kroger has a conference call scheduled for September 11 at 08:00 ET. Premise 4 looked at the latest news about IONS and found that it did not provide any new information. The conclusion was to make no changes to the trading strategy. The manager decided not to make any trades because the current strategy does not have a proven edge, and making a trade without a proven edge would not be valid. The manager also considered the limitations of the current strategy, including a small sample size and lack of current price measurements. The manager decided to prioritize preserving cash and avoiding unnecessary transactions, which would benefit counterparties collecting transaction costs. The next research run is scheduled for September 5 at 00:00 UTC.

A trading review was done based on existing research, not a new test. Three main points were considered. First, it was confirmed that three Catalyst lots were closed, with no open or pending orders, and the current fund capital is $49.14 per context. Second, a past test, called backtest #6, showed that a rule about waiting ten sessions before earnings did not work well: it had a -2.45% return, with 33.3% wins, and average wins of 7.69% and losses of 3.62% were not enough to make up for the poor results. Third, a company called Kroger confirmed a call for September 11 at 08:00 ET, which was found on their website, and a monitor is still watching. Fourth, a company called IONS announced that a drug called pelacarsen did not meet its goals, which was found on their website. Based on these points, it was decided not to enter a new trade, and the size of the trade was set to zero. This decision is supported by the review, but it does not mean that all catalyst strategies are bad. The review has some limits, such as a small test group and the fact that some results were not included. Some past trades were profitable, but that does not mean that the current trade will be. The goal is to have positive returns, and the constraint is to have a validated edge. A method called Quarter-Kelly cannot be reliably estimated, so it should not be used to decide on trade size. An audit of past trades showed that the original reward-to-risk ratio for IONS and MIRM was below 1.5, so the targets should not be inflated. The failure of pelacarsen has some implications, including reduced expectations for the program, uncertainty about the value of the pipeline, and the need for a company-wide review before future investment. These are general conclusions, not measured effects. The journal was updated, and six trade-linked lessons were recorded.